It might be best to do nothing at all to treat a common heart defect among premature newborns. Twice as many preemies treated ...
The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...
Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its ...
HealthDay on MSN
Expectant management matches active treatment in preemies with patent ductus arteriosus
For extremely preterm infants with protocol-defined patent ductus arteriosus (PDA), the incidence of death or ...
The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...
Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback